High Katherine A 4

What Happened
Katherine A. High, a director of CRISPR Therapeutics AG (CRSP), received an award of derivative securities covering 13,000 shares on June 5, 2026. The grant is recorded at $0.00 (no cash paid) and represents a compensatory option/award rather than an open-market purchase or sale.

Key Details

• Transaction date: June 5, 2026; Form 4 filed: June 9, 2026 (timely filing).
• Security: 13,000 derivative shares awarded; reported price $0.00 (grant).
• Shares owned after transaction: Not specified in the filing.
• Footnote: Award vests in 12 equal monthly installments, with the first installment vesting June 30, 2026, and the final installment vesting on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting. Vesting is conditioned on continued service.
• No indication in the filing of an immediate exercise, sale, tax-withholding, or a 10b5-1 plan.

Context
This was a compensatory grant to a director and not a cash purchase or sale; such awards are routine for executive/director compensation and are subject to service-based vesting. Because the award vests over time, the shares are not fully exercisable immediately and do not reflect an immediate change in insider ownership liquidated on the market.